theMednetRegister

ESMO 2025   

Questions discussed in this category



Papers discussed in this category

N Engl J Med, 2022 Jan 19
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
Lancet (London, England), 2025 Jun 02
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.
Journal of gynecologic oncology, 2025 Jul
Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial.
The Lancet. Oncology, 2022 Jun 09
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
Annals of oncology : official journal of the European Society for Medical Oncology, 2025 Oct 18
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial.
The New England journal of medicine, 2025 Oct 19
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.
Future oncology (London, England), 2023 Aug 01
TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.
J. Clin. Oncol., 2020 Sep 20
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
The New England journal of medicine, 2024 Mar 21
Ribociclib plus Endocrine Therapy in Early Breast Cancer.
The New England journal of medicine, 2025 May 31
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer.
The New England journal of medicine, 2025 Oct 29
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.
The New England journal of medicine, 2025 Oct 20
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.
The New England journal of medicine, 2025 Oct 19
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer.
Lancet Oncol, 2021 Mar 12
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
Future oncology (London, England), 2025 Nov 13
BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line V600E-mutant metastatic colorectal cancer.
Lancet (London, England), 2025 Oct 20
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial.
J Clin Oncol, 2019 Jun 02
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.
The New England journal of medicine, 2025 Oct 19
Sacituzumab Tirumotecan in EGFR-TKI-Resistant, -Mutated Advanced NSCLC.
Annals of oncology : official journal of the European Society for Medical Oncology, 2025 Oct 17
\zaAlectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: Final overall survival analysis of the Phase III ALEX study.
The New England journal of medicine, 2025 Dec 10
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.
BMJ open, 2025 Aug 27
Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE.
N Engl J Med,
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
Future oncology (London, England), 2021 May 19
Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303.

Related Topics

Copyright © 2026 theMednet
All Rights Reserved.